Acquired biotech accuses Novartis of letting IL-15 asset ‘wither on the vine’

Novartis is being accused of deliberately stalling the development of an acquired IL-15 asset, costing a smaller biotech up to $940 million in milestone payments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis eyes first-line status for its radionucleotide therapy Lutathera – Pharmaceutical Technology

Both of Novartis’ NET therapies were top 20 high-grossing drugs for the company, with Sandostatin and Lutathera generating $660m and $299m in H2 2023. Image

September 25, 2023

Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer

November 5, 2024

Reneo cuts 70% of staff following Phase III trial failure

Share this article Following the news, Reneo’s stock was down by 478% at the market close on 14 December, compared to the market close on

December 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.